The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma

Muszbek, N; Kadambi, A; Lanitis, T; Hatswell, AJ; Patel, D; Wang, L; Singer, JW; Muszbek, N; Kadambi, A; Lanitis, T; Hatswell, AJ; Patel, D; Wang, L; Singer, JW; Pettengell, R; - view fewer (2016) The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma. Clinical Therapeutics , 38 (3) pp. 503-515. 10.1016/j.clinthera.2016.01.004 . Green open access

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2ap0WY6
via IFTTT